11 results about "Gestational hypertension" patented technology

The invention discloses a preparation method of a medicinal and edible traditional Chinese medicine composition for preventing and treating pregnancy complications. The medicinal and edible traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 24 parts of radix rehmanniae, 12 parts of fructus gardeniae and 9 parts of folium mori. The composition embodies the essence of compatibility of monarch, minister, assistant and guide of a traditional Chinese medicine compound, the radix rehmanniae is used as a monarch drug, the fructus gardeniae is used as a minister drug, the folium mori is used as an assistant drug, and the composition is mainly characterized by nourishing the kidney, containing wood, clearing away fire, calming the liver and lightly dredging upper jiao and exactly conforms to the core pathogenesis of yin deficiency and yang hyperactivity of gestational hypertension. Modern pharmacological experiments prove that the three traditional Chinese medicinal materials all have definite antihypertensive activity, and the action mechanism shows the characteristic of multi-target synergism. The raw materials in the formula are homologous in medicine and food, free of toxic and side effects, mild in medicine property and capable of considering fetal elements, the three medicines all belong to clinical common miscarriage prevention or miscarriage prevention categories, worries about blood breaking and fetal movement are avoided, and the traditional Chinese medicine is suitable for being used in the pregnancy stage. The pharmaceutical composition disclosed by the invention can be used for relieving clinical symptoms of hypertensive patients in pregnancy and improving the outcome of bad pregnancy.

This invention relates to a group of genes associated with gestational hypertension, a method for predicting gestational hypertension in early pregnancy using these genes, and related applications. Specifically, this invention obtains transcript start site feature values ​​from at least one of the following genes from the cfDNA sample of a pregnant woman: LOC124902572, EEF1A1P16, LOC105369767, GOLM2, CDRT7, MEIS3, and LOC105376108. These transcript start site feature values ​​are then input into a prediction model, and the output results are used to determine the risk of gestational hypertension. The number of sequences in the transcript start site region after correction based on the transcript start site feature values ​​is also considered. The prediction model obtained by this invention can effectively and robustly predict the risk of gestational hypertension (including preeclampsia) in early pregnancy, assisting doctors in early pregnancy intervention and reducing the risk of gestational hypertension.

The present invention relates to determining the carrier status of Annexin A5 M2 haplotype of parents (both male and female) prior to and / or after pregnancy to minimize the risk of pregnancy complications, including, but not limited to, recurrent pregnancy loss (RPL), infertility, miscarriage, in vitro fertilization (IVF) failure, IUI failure, implantation failure, foetal growth restriction (FGR), small for gestational age (SGA) newborn, intra-uterine foetal death (IUFD), gestational hypertension (GH), pre-eclampsia (PE) and / or venous thromboembolism (VTE). Once M2 carrier status is determined, methods of intervention, including administration of low molecular weight heparin (LMWH) and / or other anti-coagulants can be administered either prior to and / or after pregnancy. Methods of detecting the carrier status as well as method of diagnosing and or predicting prognosis based on the M2 carrier status of a patient and / or couple is also contemplated.

The invention discloses a blood mtDNACN-based system, method and application for evaluating an adverse pregnancy outcome risk, and the system comprises a data obtaining module which is used for obtaining blood mtDNACN detection data; the risk assessment module is used for storing a pre-constructed causal risk assessment model; and the result output module is used for outputting a risk assessment result. The model is constructed based on a Mendel randomization method, SNP significantly related to blood mtDNACN is used as a tool variable, and the lactic acid metabolism level hybrid effect is innovatively corrected, so that the lactic acid metabolism level hybrid effect of a subject is corrected without depending on lactic acid parameters of the subject. The causal association between the blood mtDNACN and the specific adverse pregnancy outcome (including gestational hypertension, preeclampsia, premature rupture of fetal membranes and the like) is accurately determined. According to the scheme provided by the invention, more reliable and anti-hybrid individualized risk assessment can be realized, and a new tool is provided for health management in the gestation period.

The application discloses a kind of classification model generation method and device for predicting gestational hypertension, and the method one specific embodiment includes: carrying label fundus image as first training sample, obtain first sample dataset;Wherein, label includes normal label and gestational hypertension label;Gestational hypertension label includes: early gestational hypertension label, mild preeclampsia label and severe preeclampsia label;Based on first sample dataset, model training is generated two-classification model;And according to the gestational hypertension classification result obtained by second classification model to first sample dataset prediction, obtain second sample dataset;Then based on second sample dataset, model training is generated three-classification model;Finally, based on two-classification model and three-classification model, gestational hypertension classification model is generated.Therefore, the difficulty of model to the recognition of gestational hypertension is effectively reduced, and the accuracy of gestational hypertension classification is improved.

The invention provides an intelligent prediction system and method for prenatal complications of an obstetrical department based on multi-modal fusion of sclera characteristics and clinical indexes, and is applied to the technical field of data processing. The method comprises the following steps: performing preprocessing and fusion calculation on feature information in multi-modal data to generate fusion calculation data; the prenatal complications (such as gestational diabetes mellitus, gestational hypertension, premature rupture of fetal membranes and premature delivery) of the obstetrics department are dynamically predicted, and prediction characteristic parameters are generated; performing abnormal value filtering processing on the cross-modal feature weight, dynamically optimizing the weight in combination with a clinical and image feature correlation matrix, and generating feature weight data; processing the feature weight data to generate feature importance dynamic change data and abnormal features; processing the feature importance dynamic change data based on a preset risk judgment rule and the abnormal features to generate risk judgment data; and processing the risk judgment data and the prediction characteristic parameters to generate risk early warning information and a complication intervention instruction.

The invention discloses a blood vessel morphological characteristic quantification method based on an eye fundus image and a gestational hypertension detection device. The method comprises the following steps: firstly, carrying out preprocessing and blood vessel enhancement on a collected fundus image, then extracting a blood vessel structure, extracting diameter characteristics, gray intensity characteristics and morphological characteristics of a blood vessel, and judging the type of the blood vessel through a two-stage classification strategy. The first stage performs classification based on a diameter threshold. And for the case that the blood vessel diameter characteristic value is in the middle range boundary, in combination with context information, through constructing a Gaussian probability scoring function, calculating the matching degree score of the blood vessel characteristics and the artery and vein reference characteristics, and realizing two-stage fine classification. And finally, a blood vessel center line topological structure is obtained through a skeletonization extraction algorithm, and the parting dimension and the blood vessel curvature of the blood vessel are calculated in combination with the blood vessel structure. The gestational hypertension detection device uses a result obtained by the blood vessel morphological feature quantification method as a multi-dimensional feature parameter, and predicts a hypertension risk probability by using a classification model.

The invention is applicable to the technical field of biological medicine, and provides application of a traditional Chinese medicine monomer in preparation of a medicine for treating preeclampsia, the traditional Chinese medicine monomer is rhynchophylline, and the rhynchophylline is clear in source, high in safety and pure in structure. Retrieval shows that no research report or patent disclosure for the rhynchophylline for preeclampsia treatment exists at present, and no systematic evaluation of the rhynchophylline under a multi-model system exists. According to the invention, a multi-model system is constructed for the first time, the intervention effect of the rhynchophylline on the preeclampsia is systematically evaluated, and the situation that the rhynchophylline can remarkably improve gestational hypertension, reduce the urine protein level and repair placenta structure and functional damage is found, so that effective intervention on the preeclampsia is realized. The invention fills the technical blank in the field, has a good application prospect, and provides a safe and controllable natural active ingredient and an application scheme thereof for preeclampsia.

The invention discloses a biomarker composition and application thereof, and belongs to the field of biomarker analysis and detection. The invention firstly provides a group of biomarker compositions, wherein the biomarker compositions comprise a Klotho protein and a neutrophil gelatinase associated lipocalin (NGAL); the combined detection biomarker composition can be used for early assessment of the risk of hypertensive disorder in pregnancy complicated with acute kidney injury. When the marker composition is used for predicting the risk of hypertensive disorder in pregnancy complicated with acute kidney injury, the risk of acute kidney injury can be recognized in advance in the early pregnancy stage.

The intrauterine hemostasis balloon comprises a guiding assembly and a liquid injection assembly, the guiding assembly comprises a guiding head, a bulb and a flexible catheter, the guiding assembly is used for guiding the intrauterine hemostasis balloon, the guiding head is fixedly connected to the top end of the flexible catheter, and the bulb is fixedly connected to the liquid injection assembly. The guide head penetrates through the bulb and is fixedly connected with the outer surface of the bulb, the interior of the bulb is hollow, the flexible guide pipe penetrates through the bulb and is fixedly connected with the bulb, the liquid injection assembly is jointly composed of a first one-way valve, a sleeve, a piston rod, a liquid injection bag and a connecting pipe, and the liquid injection assembly is used for injecting liquid into the bulb. The first one-way valve is fixedly connected to the flexible guide pipe in series, and the sleeve is connected with the piston rod in a sleeved mode. According to the device, the guide head is arranged, so that the uterus of a puerpera cannot be scratched when the device is used, and the problem that the uterus of the puerpera is stimulated due to scraping is solved.

The application provides a traditional Chinese medicine composition for treating or improving pregnancy-induced hypertension, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from traditional Chinese medicine raw materials of Gyrinopsys pentaphylla, Radix Rehmanniae Preparata, Apocynum venetum, Inula helenium, schreyberite, Dipsacus asper, Taxillus sutchuenensis, root of Boehmeria nivea, Fructus Amomi Rotundus and Perilla frutescens. The traditional Chinese medicine composition can significantly reduce the tail artery pressure, 24h urine protein and inflammatory factor level of a pregnancy-induced hypertension rat, significantly improve the adverse pregnancy outcome of a pregnant rat caused by hypertension, and has a significant treatment effect on a pregnancy-induced hypertension rat model. The traditional Chinese medicine composition is expected to become a new drug for treating pregnancy-induced hypertension.